• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脉络膜无灌注和杆状细胞变性在 3 型黄斑新生血管发病机制中的潜在关键作用。

The potential key role of choroidal non-perfusion and rod degeneration in the pathogenesis of macular neovascularization type 3.

机构信息

Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.

出版信息

Eye (Lond). 2024 Jul;38(10):1836-1839. doi: 10.1038/s41433-024-03034-z. Epub 2024 Mar 18.

DOI:10.1038/s41433-024-03034-z
PMID:38499856
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11226597/
Abstract

Macular neovascularization type 3 (MNV3) is a multifactorial disease with distinct epidemiological, clinical, pathomorphological and topographical characteristics. This review of the literature discusses the latest experimental and clinical outcomes that could explain the pathogenesis of retinal neovascularization. Although patients with MNV3 are usually older than those with MNV1 or 2, their lesions do not coexist with, precede, or follow other types in the same eye. The regional distribution of MNV3 lesions is characterized as confined to the parafoveal macula without any involvement of the rod-free foveal area. Focal outer retinal atrophy and choroidal non-perfusion are the main structural features that occur prior to the development of retinal neovascularization. Also, histological and experimental studies of MNV3 and other non-neovascular age-related macular degeneration diseases complicated with MNV3-like lesions strongly suggest rod degeneration contributes to the pathogenesis. Therefore, the retinal neovascularization in MNV3 has a different pathogenesis from the choroidal neovascularization in MNV1 and 2 and emerging evidence indicates that choroidal non-prefusion and rod degeneration play a key role in the pathogenesis of MNV3. Accordingly, we suggest a sequence of pathological events that start with choroidal non-perfusion due to advanced age followed by hypoxia of the outer retina at the parafoveal area. This induces a remarkable degeneration of rods that triggers the growth of retinal neovascularization due to the imbalance of the angiogenic factors in the outer retina.

摘要

黄斑新生血管 3 型(MNV3)是一种多因素疾病,具有独特的流行病学、临床、病理形态学和解剖学特征。本文对文献进行综述,讨论了最新的实验和临床结果,这些结果可以解释视网膜新生血管形成的发病机制。虽然 MNV3 患者通常比 MNV1 或 MNV2 患者年龄更大,但他们的病变并不与同一眼中的其他类型共存、先于或继其他类型之后。MNV3 病变的区域分布特征为局限于旁中心凹,黄斑区无任何杆状细胞无血管区受累。局灶性外视网膜萎缩和脉络膜无灌注是在视网膜新生血管形成之前发生的主要结构特征。此外,对 MNV3 及其他伴有 MNV3 样病变的非新生血管性年龄相关性黄斑变性疾病的组织学和实验研究强烈表明,杆状细胞变性有助于发病机制。因此,MNV3 中的视网膜新生血管形成与 MNV1 和 MNV2 中的脉络膜新生血管形成具有不同的发病机制,新出现的证据表明脉络膜无灌注和杆状细胞变性在 MNV3 的发病机制中起关键作用。因此,我们提出了一系列病理事件的顺序,首先是由于年龄增长导致脉络膜无灌注,接着是旁中心凹外视网膜缺氧,这会引起杆状细胞明显变性,由于外视网膜中血管生成因子的失衡,导致视网膜新生血管的生长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8b7/11226597/ef38b0a7d33d/41433_2024_3034_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8b7/11226597/ef38b0a7d33d/41433_2024_3034_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8b7/11226597/ef38b0a7d33d/41433_2024_3034_Fig1_HTML.jpg

相似文献

1
The potential key role of choroidal non-perfusion and rod degeneration in the pathogenesis of macular neovascularization type 3.脉络膜无灌注和杆状细胞变性在 3 型黄斑新生血管发病机制中的潜在关键作用。
Eye (Lond). 2024 Jul;38(10):1836-1839. doi: 10.1038/s41433-024-03034-z. Epub 2024 Mar 18.
2
THE RAP STUDY, REPORT 5: REDISCOVERING MACULAR NEOVASCULARIZATION TYPE 3: Multimodal Imaging of Fellow Eyes over 24 months.RAP 研究,报告 5:重新发现黄斑新生血管 3 型:24 个月以上对侧眼的多模态成像。
Retina. 2022 Mar 1;42(3):485-493. doi: 10.1097/IAE.0000000000003330.
3
THE RAP STUDY, REPORT TWO: The Regional Distribution of Macular Neovascularization Type 3, a Novel Insight Into Its Etiology.RAP 研究,报告二:3 型黄斑新生血管的区域性分布,对其病因的新认识。
Retina. 2020 Dec;40(12):2255-2262. doi: 10.1097/IAE.0000000000002774.
4
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration.当前对与年龄相关性黄斑变性相关的 3 型黄斑新生血管的认识。
Ophthalmologica. 2024;247(2):73-84. doi: 10.1159/000536278. Epub 2024 Jan 24.
5
Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model.在亚视网膜脂质诱导的年龄相关性黄斑变性模型中,脉络膜和视网膜中的氧化应激、炎症和新生血管的演变。
Exp Eye Res. 2021 Feb;203:108391. doi: 10.1016/j.exer.2020.108391. Epub 2020 Dec 8.
6
The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3.RAP 研究,报告 3:3 型黄斑新生血管患者黄斑区变色。
Acta Ophthalmol. 2022 Feb;100(1):e270-e277. doi: 10.1111/aos.14866. Epub 2021 Apr 5.
7
RAP study, report 1: novel subtype of macular neovascularisation type III, cilioretinal MNV3.RAP 研究,报告 1:新型 III 型黄斑新生血管亚型,脉络膜睫状 MNV3。
Br J Ophthalmol. 2021 Jan;105(1):113-117. doi: 10.1136/bjophthalmol-2019-315311. Epub 2020 Mar 11.
8
IMPROVING THE AGE-RELATED MACULAR DEGENERATION CONSTRUCT: A New Classification System.改善年龄相关性黄斑变性的构建:一个新的分类系统。
Retina. 2018 May;38(5):891-899. doi: 10.1097/IAE.0000000000001732.
9
Chronic Dicer1 deficiency promotes atrophic and neovascular outer retinal pathologies in mice.慢性 Dicer1 缺乏症促进小鼠萎缩性和新生血管性外视网膜病变。
Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2579-2587. doi: 10.1073/pnas.1909761117. Epub 2020 Jan 21.
10
Anaphylatoxin Signaling in Retinal Pigment and Choroidal Endothelial Cells: Characteristics and Relevance to Age-Related Macular Degeneration.过敏毒素信号在视网膜色素上皮和脉络膜内皮细胞中的作用:特征及与年龄相关性黄斑变性的相关性。
Adv Exp Med Biol. 2018;1074:45-51. doi: 10.1007/978-3-319-75402-4_6.

本文引用的文献

1
Histology of Type 3 Macular Neovascularization and Microvascular Anomalies in Treated Age-Related Macular Degeneration: A Case Study.治疗后的年龄相关性黄斑变性中3型黄斑新生血管形成和微血管异常的组织学:一项病例研究
Ophthalmol Sci. 2023 Feb 10;3(3):100280. doi: 10.1016/j.xops.2023.100280. eCollection 2023 Sep.
2
Biologically Guided Optimization of Test Target Location for Rod-mediated Dark Adaptation in Age-related Macular Degeneration: Alabama Study on Early Age-related Macular Degeneration 2 Baseline.年龄相关性黄斑变性中视杆介导暗适应测试目标位置的生物引导优化:阿拉巴马州早期年龄相关性黄斑变性研究2基线
Ophthalmol Sci. 2023 Jan 23;3(2):100274. doi: 10.1016/j.xops.2023.100274. eCollection 2023 Jun.
3
Nascent Geographic Atrophy as a Predictor of Type 3 Macular Neovascularization Development.
新生性地理萎缩作为3型黄斑新生血管形成的预测指标
Ophthalmol Retina. 2023 Jul;7(7):586-592. doi: 10.1016/j.oret.2023.01.019. Epub 2023 Feb 2.
4
Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?单侧黄斑新生血管 3 型患者是否需要 AREDS 补充剂来减缓向年龄相关性黄斑变性的进展?
Eye (Lond). 2023 Jun;37(9):1751-1753. doi: 10.1038/s41433-022-02249-2. Epub 2022 Sep 29.
5
THE RAP STUDY, REPORT 5: REDISCOVERING MACULAR NEOVASCULARIZATION TYPE 3: Multimodal Imaging of Fellow Eyes over 24 months.RAP 研究,报告 5:重新发现黄斑新生血管 3 型:24 个月以上对侧眼的多模态成像。
Retina. 2022 Mar 1;42(3):485-493. doi: 10.1097/IAE.0000000000003330.
6
Clinical Pathological Features and Current Animal Models of Type 3 Macular Neovascularization.3型黄斑新生血管的临床病理特征及当前动物模型
Front Neurosci. 2021 Aug 26;15:734860. doi: 10.3389/fnins.2021.734860. eCollection 2021.
7
The RAP study, report 4: morphological and topographical characteristics of multifocal macular neovascularization type 3.RAP 研究,报告 4:多灶性黄斑新生血管病变 3 型的形态学和解剖学特征。
Graefes Arch Clin Exp Ophthalmol. 2022 Jan;260(1):141-147. doi: 10.1007/s00417-021-05332-8. Epub 2021 Aug 26.
8
Choriocapillaris: Fundamentals and advancements.脉络膜毛细血管:基础与进展。
Prog Retin Eye Res. 2022 Mar;87:100997. doi: 10.1016/j.preteyeres.2021.100997. Epub 2021 Jul 19.
9
The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3.RAP 研究,报告 3:3 型黄斑新生血管患者黄斑区变色。
Acta Ophthalmol. 2022 Feb;100(1):e270-e277. doi: 10.1111/aos.14866. Epub 2021 Apr 5.
10
BASELINE PREDICTORS ASSOCIATED WITH 3-YEAR CHANGES IN DARK ADAPTATION IN AGE-RELATED MACULAR DEGENERATION.与年龄相关性黄斑变性的暗适应 3 年变化相关的基线预测因素。
Retina. 2021 Oct 1;41(10):2098-2105. doi: 10.1097/IAE.0000000000003152.